UM1DA058236

New York Genome Characterization Center: Somatic Mosaicism Across Human Tissues - Project Summary/Abstract

New York Genome Characterization Center large-scale sequencing efforts over the last two decades have been focused on generating DNA sequence datasets from readily available tissues such as blood or saliva to identify germline variants associated with disease phenotypes. However, limited progress has been made in characterizing somatic variants in healthy tissues and their contribution to health and disease over the course of the human lifespan.

Somatic variation has historically been studied in the context of tumor biology; however, there is mounting evidence that somatic variation plays an important role in the aging process, as well as in cardiovascular, neurodegenerative, immunologic, and neurodevelopmental diseases. There is therefore a critical need to characterize the somatic variant landscape in healthy human tissues in individuals of diverse race and ethnicity across the human lifespan.

The Somatic Mosaicism Across Human Tissues (SMAHT) program will address this gap by establishing a cohesive network that will work together to create a high-quality somatic variant catalog. This catalog will be broadly shareable across the scientific community and will enable studies investigating the rates and patterns of somatic mosaicism across cell populations and tissues. It will also elucidate the mechanisms underlying clonal development, evolution, and expansion, and enable studies of the role of somatic mutation in disease pathogenesis and progression.

The New York Genome Characterization Center (NYGCC) will work collaboratively with other SMAHT network centers to generate a high-quality somatic variant catalog using three core high-depth sequencing assays: duplex whole genome sequencing (WGS), mRNA sequencing, and long-read Oxford Nanopore WGS. These three core assays will provide an unprecedented and comprehensive view of somatic mutations across a variety of healthy tissues.

The data from deep WGS will enable the discovery of somatic single nucleotide variants (SNVs), insertions and deletions (indels), mobile elements, copy number changes, and structural variants. The RNA sequencing data will be used to confirm the presence of those variants that fall in expressed genes and further evaluate their effect on splicing. The long-read WGS sequencing will be used as a corollary to short-read WGS to confirm and enhance the discovery of mobile elements, copy number changes, and structural variants.

To these core assays, we propose adding single-cell WGS sequencing using direct library preparation plus (DLP+) and genotyping of transcriptomes (GOT). DLP+ is an amplification-free single-cell WGS assay that allows high sensitivity detection of copy number changes, loss of heterozygosity, and structural variation. It further enables the study of replication timing, clonal expansion, and fitness and is compatible with pooled pseudo-bulk analysis to compare against deep bulk WGS. The genotyping of transcriptomes assay will allow us to explore, for expressed somatic variants, the cell type or lineage in which they occurred. By pairing with single-cell expression data (and cell surface marker detection and long-read transcript sequencing), we can investigate the functional effects of these mutations.

New York Genome Center

NOT APPLICABLE

93.310 - Trans-NIH Research Support

National Institute on Drug Abuse (NIDA) [HHS - NIH]

National Institute of Allergy and Infectious Diseases (NIAID) [HHS - NIH]

New York United States

State-Wide

Somatic Mosaicism across Human Tissues (SMaHT) Program: Genome Characterization Centers (UM1 Clinical Trial Not Allowed) (RFA-RM-22-013)

Amendment Since initial award the End Date has been extended from 04/30/25 to 04/30/26 and the total obligations have increased 100% from $1,500,000 to $3,000,000.